CLINICAL TRIALS PROFILE FOR DYNACIN
✉ Email this page to a colleague
All Clinical Trials for Dynacin
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00473083 ↗ | Systemic and Topical Treatments for Rash Secondary to Erlotinib in Lung Cancer | Completed | Hoffmann-La Roche | Phase 2 | 2009-01-01 | The purpose of this trial is to determine if rash caused by erlotinib can be successfully treated and if so to determine the optimal treatment approach. Hypothesis: Hypothesis 1: If the incidence of rash is 50% while on erlotinib, prophylactic monotherapy with minocycline can prevent occurrence in 50% of these patients. Hypothesis 2: Treatment of rash is successful in improving rash by at least one Grade in 80% of patients. Hypothesis 3: In patients with untreated rash, the rash will be self-limiting in 25% of patients, and 65% will be grade 1, 2A, and 2b. Ten percent will be grade 3 requiring treatment with monotherapy intervention. |
| NCT00473083 ↗ | Systemic and Topical Treatments for Rash Secondary to Erlotinib in Lung Cancer | Completed | British Columbia Cancer Agency | Phase 2 | 2009-01-01 | The purpose of this trial is to determine if rash caused by erlotinib can be successfully treated and if so to determine the optimal treatment approach. Hypothesis: Hypothesis 1: If the incidence of rash is 50% while on erlotinib, prophylactic monotherapy with minocycline can prevent occurrence in 50% of these patients. Hypothesis 2: Treatment of rash is successful in improving rash by at least one Grade in 80% of patients. Hypothesis 3: In patients with untreated rash, the rash will be self-limiting in 25% of patients, and 65% will be grade 1, 2A, and 2b. Ten percent will be grade 3 requiring treatment with monotherapy intervention. |
| NCT01048983 ↗ | Reducing Symptom Burden - Non Small Cell Lung Cancer (NSCLC) | Withdrawn | National Cancer Institute (NCI) | Phase 1/Phase 2 | 1969-12-31 | The goal of this clinical research study is to compare armodafinil, bupropion, curcumin, and minocycline when given alone or in combination to learn which is better for controlling symptoms, such as the side effects of chemoradiation, when given to treat lung cancer. |
| NCT01048983 ↗ | Reducing Symptom Burden - Non Small Cell Lung Cancer (NSCLC) | Withdrawn | M.D. Anderson Cancer Center | Phase 1/Phase 2 | 1969-12-31 | The goal of this clinical research study is to compare armodafinil, bupropion, curcumin, and minocycline when given alone or in combination to learn which is better for controlling symptoms, such as the side effects of chemoradiation, when given to treat lung cancer. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Dynacin
Condition Name
Clinical Trial Locations for Dynacin
Trials by Country
Clinical Trial Progress for Dynacin
Clinical Trial Phase
Clinical Trial Sponsors for Dynacin
Sponsor Name
